Overview

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

Status:
RECRUITING

Trial end date:
2029-08-31

Target enrollment:

Participant gender:

Summary

To learn if olutasidenib, when combined with a drug called a hypomethylating agent (HMA) can help to control MDS, CMML, and/or MPN. The safety of the drug combination will also be studied.

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Rigel Pharmaceuticals

Treatments:

olutasidenib